Panacea Biotec Q3 net loss at 71.72 cr
The company had posted a net profit of Rs 42.60 crore for the quarter ended December 31, 2010, Panacea Biotec said in a filing to BSE.
By PTI | Updated:
NEW DELHI: Drug firm Panacea Biotec on Friday reported a net loss of Rs 71.72 crore for the quarter ended December 31, 2011, mainly due to delisting of the company's pentavalent vaccine by the World Health Organisation (WHO).
The company had posted a net profit of Rs 42.60 crore for the quarter ended December 31, 2010, Panacea Biotec said in a filing to BSE.
"The current performance continues to be affected due to the delisting of the pentavalent vaccine, following a routine site audit by a WHO team in July 2011," Panacea Biotec Joint Managing Director Rajesh Jain said.
Total income of the company stood at Rs 155.16 crore for the quarter under consideration. It was Rs 292.81 crore for the corresponding period in the previous fiscal.
Shares of Panacea Biotec today closed at Rs 89.05 on BSE, up 0.56 per cent from its previous close.
The company had posted a net profit of Rs 42.60 crore for the quarter ended December 31, 2010, Panacea Biotec said in a filing to BSE.
"The current performance continues to be affected due to the delisting of the pentavalent vaccine, following a routine site audit by a WHO team in July 2011," Panacea Biotec Joint Managing Director Rajesh Jain said.
Total income of the company stood at Rs 155.16 crore for the quarter under consideration. It was Rs 292.81 crore for the corresponding period in the previous fiscal.
Shares of Panacea Biotec today closed at Rs 89.05 on BSE, up 0.56 per cent from its previous close.
Too busy to trade in stocks? Invest in Mutual Funds with ET Money!
Bookmark or read stories offline -
Download ET Markets APP
Download ET Markets APP
Related Articles
Panacea Biotec Q3 net profit at Rs 83 croreADVERTISEMENT
